The IMpactMF trial was discontinued after an independent committee determined imetelstat was unlikely to improve overall ...
Zev A. Wainberg, MD, MSc, reviews RASolute 302 findings on daraxonrasib's OS benefit across RAS genotypes in metastatic pancreatic cancer.
COA urges Supreme Court review of Mississippi 340B contract pharmacy law, spotlighting PBM influence, drug access concerns, and calls for tighter oversight.
Bhavana Pothuri, MD, discusses TroFuse-005 at ESMO 2026, including TROP2 expression, treatment sequencing, and the future of ...
Lauren Banks, MD, PhD, discusses TIL therapy feasibility and safety in dedifferentiated liposarcoma and undifferentiated ...
Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, addresses whether biomarker testing is needed to ...
Torvu-Sam is moving into phase 3 trials at a dose of 2 mg/kg. In PROC, it will be compared with mirvetuximab soravtansine in ...
A biologics license application (BLA) has been submitted to the FDA for etentamig (ABBV-383), an investigational BCMA x CD3 ...
Targeted Oncologyâ„¢ is a leading omnichannel resource for community oncologists, offering innovative learning and peer interaction through print and digital platforms. Our custom programs meet your ...
Five phase 3 analyses presented as late-breaking abstracts at the 2026 European Society for Medical Oncology (ESMO) Congress ...
ADCs improved on chemotherapy-based regimens in PD-L1–negative and EGFR-mutated NSCLC, while chemotherapy plus pembrolizumab ...
Bhavana Pothuri, MD, discusses phase 3 TroFuse-005 data from ESMO, where sac-TMT improved PFS and OS vs chemotherapy in endometrial cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results